메뉴 건너뛰기




Volumn 18, Issue 4, 2012, Pages 1177-1185

Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan

Author keywords

[No Author keywords available]

Indexed keywords

CELL FREE DNA; CETUXIMAB; DNA; IRINOTECAN; UNCLASSIFIED DRUG;

EID: 84857076207     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0564     Document Type: Article
Times cited : (230)

References (25)
  • 1
    • 59949091448 scopus 로고    scopus 로고
    • Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
    • Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-71.
    • (2009) J Clin Oncol , vol.27 , pp. 663-671
    • Bokemeyer, C.1    Bondarenko, I.2    Makhson, A.3    Hartmann, J.T.4    Aparicio, J.5    De Braud, F.6
  • 3
    • 78149250536 scopus 로고    scopus 로고
    • Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study
    • Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-705.
    • (2010) J Clin Oncol , vol.28 , pp. 4697-4705
    • Douillard, J.Y.1    Siena, S.2    Cassidy, J.3    Tabernero, J.4    Burkes, R.5    Barugel, M.6
  • 6
    • 42649145667 scopus 로고    scopus 로고
    • Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    • Amado RG, Wolf M, Peeters M, Van CE, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
    • (2008) J Clin Oncol , vol.26 , pp. 1626-1634
    • Amado, R.G.1    Wolf, M.2    Peeters, M.3    Van, C.E.4    Siena, S.5    Freeman, D.J.6
  • 7
    • 77955277111 scopus 로고    scopus 로고
    • Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis
    • De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62.
    • (2010) Lancet Oncol , vol.11 , pp. 753-762
    • De Roock, W.1    Claes, B.2    Bernasconi, D.3    De Schutter, J.4    Biesmans, B.5    Fountzilas, G.6
  • 8
    • 33646228635 scopus 로고    scopus 로고
    • KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
    • Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5.
    • (2006) Cancer Res , vol.66 , pp. 3992-3995
    • Lièvre, A.1    Bachet, J.B.2    Le Corre, D.3    Boige, V.4    Landi, B.5    Emile, J.F.6
  • 9
    • 77957205044 scopus 로고    scopus 로고
    • Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies
    • Qiu LX, Mao C, Zhang J, Zhu XD, Liao RY, Xue K, et al. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies. Eur J Cancer 2010;46:2781-7.
    • (2010) Eur J Cancer , vol.46 , pp. 2781-2787
    • Qiu, L.X.1    Mao, C.2    Zhang, J.3    Zhu, X.D.4    Liao, R.Y.5    Xue, K.6
  • 11
    • 58749102224 scopus 로고    scopus 로고
    • High concordance of KRAS status between primary colorectal tumors and related metastatic sites: Implications for clinical practice
    • Santini D, Loupakis F, Vincenzi B, Floriani I, Stasi I, Canestrari E, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 2008;13:1270-5.
    • (2008) Oncologist , vol.13 , pp. 1270-1275
    • Santini, D.1    Loupakis, F.2    Vincenzi, B.3    Floriani, I.4    Stasi, I.5    Canestrari, E.6
  • 12
    • 65549143792 scopus 로고    scopus 로고
    • The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer
    • Garm Spindler KL, Pallisgaard N, Rasmussen AA, Lindebjerg J, Andersen RF, Crüger D, et al. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol 2009;20:879-84.
    • (2009) Ann Oncol , vol.20 , pp. 879-884
    • Garm Spindler, K.L.1    Pallisgaard, N.2    Rasmussen, A.A.3    Lindebjerg, J.4    Andersen, R.F.5    Crüger, D.6
  • 13
    • 76049098292 scopus 로고    scopus 로고
    • Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases
    • Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010;16:790-9.
    • (2010) Clin Cancer Res , vol.16 , pp. 790-799
    • Baldus, S.E.1    Schaefer, K.L.2    Engers, R.3    Hartleb, D.4    Stoecklein, N.H.5    Gabbert, H.E.6
  • 14
    • 77954668198 scopus 로고    scopus 로고
    • Acquired KRAS mutations during progression of colorectal cancer metastases: Possible implications for therapy and prognosis
    • Bouchahda M, Karaboué A, Saffroy R, Innominato P, Gorden L, Guettier C, et al. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemother Pharmacol 2010;66:605-9.
    • (2010) Cancer Chemother Pharmacol , vol.66 , pp. 605-609
    • Bouchahda, M.1    Karaboué, A.2    Saffroy, R.3    Innominato, P.4    Gorden, L.5    Guettier, C.6
  • 16
    • 41649114743 scopus 로고    scopus 로고
    • Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer
    • Frattini M, Gallino G, Signoroni S, Balestra D, Lusa L, Battaglia L, et al. Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett 2008;263:170-81.
    • (2008) Cancer Lett , vol.263 , pp. 170-181
    • Frattini, M.1    Gallino, G.2    Signoroni, S.3    Balestra, D.4    Lusa, L.5    Battaglia, L.6
  • 17
    • 77956467360 scopus 로고    scopus 로고
    • Cell-free DNA in the blood as a solid tumor biomarker - A critical appraisal of the literature
    • Jung K, Fleischhacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker - A critical appraisal of the literature. Clin Chim Acta 2010;411:1611-24.
    • (2010) Clin Chim Acta , vol.411 , pp. 1611-1624
    • Jung, K.1    Fleischhacker, M.2    Rabien, A.3
  • 19
  • 21
    • 78049435890 scopus 로고    scopus 로고
    • Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts
    • Thierry A, Mouliere F, Gongore C, Ollier J, Robert B, Ychou M, et al. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res 2010;38:6159-75.
    • (2010) Nucleic Acids Res , vol.38 , pp. 6159-6175
    • Thierry, A.1    Mouliere, F.2    Gongore, C.3    Ollier, J.4    Robert, B.5    Ychou, M.6
  • 22
    • 79952006628 scopus 로고    scopus 로고
    • All about KRAS for clinical oncological practice: Gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer
    • Linardou H, Briasoulis E, Dahabreh IJ, Mountzios G, Papadimitriou C, Papadopoulos S, et al. All about KRAS for clinical oncological practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treat Rev 2011;37:221-33.
    • (2011) Cancer Treat Rev , vol.37 , pp. 221-233
    • Linardou, H.1    Briasoulis, E.2    Dahabreh, I.J.3    Mountzios, G.4    Papadimitriou, C.5    Papadopoulos, S.6
  • 23
    • 67650366758 scopus 로고    scopus 로고
    • Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer
    • Yen LC, Yeh YS, Chen CW, Wang HM, Tsai HL, Lu CY, et al. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.Clin Cancer Res 2009;15:4508-13.
    • (2009) Clin Cancer Res , vol.15 , pp. 4508-4513
    • Yen, L.C.1    Yeh, Y.S.2    Chen, C.W.3    Wang, H.M.4    Tsai, H.L.5    Lu, C.Y.6
  • 24
    • 22244472992 scopus 로고    scopus 로고
    • Poor survival associated with the BRAF V600E mutation in microsatelite-stable colon cancers
    • Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, et al. Poor survival associated with the BRAF V600E mutation in microsatelite-stable colon cancers. Cancer Res 2005;14:6063-9.
    • (2005) Cancer Res , vol.14 , pp. 6063-6069
    • Samowitz, W.S.1    Sweeney, C.2    Herrick, J.3    Albertsen, H.4    Levin, T.R.5    Murtaugh, M.A.6
  • 25
    • 56649084987 scopus 로고    scopus 로고
    • Comprehensive biostatistical analysis of CgP island methylator phenotype in colorectal cancer using an large population-based sample
    • Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, et al. Comprehensive biostatistical analysis of CgP island methylator phenotype in colorectal cancer using an large population-based sample. PLoS One 2008;11:e3698.
    • (2008) PLoS One , vol.11
    • Nosho, K.1    Irahara, N.2    Shima, K.3    Kure, S.4    Kirkner, G.J.5    Schernhammer, E.S.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.